US FDA To Increase Surveillance Of Pharmaceutical Manufacturing Sites In Poor-Quality Countries

Agency revises internal guidance to incorporate statutory requirement for greater scrutiny of drug manufacturing facilities in countries where past experience demonstrates overall quality is low. Revised MAPP also allows for inspection deferral at sites that have superior quality systems.

Sullied though spotless
sullied by neighbors no matter how pristine • Source: Shutterstock

The Office of Pharmaceutical Quality in the US Food and Drug Administration’s Center for Drug Evaluation and Research has instructed its staff to follow through on a legislative requirement to regard pharmaceutical manufacturing facilities more suspiciously if they are in countries where such facilities generally have relatively poor compliance histories.

The provision is one of several inspection-related measures in Section 3613 of the Food and Drug Omnibus Reform Act, which...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance